Travere Therapeutics (TVTX) Gross Profit (2014 - 2026)

Travere Therapeutics' Gross Profit history runs 13 years deep, the most recent figure standing at $125.2 million for Q1 2026.

• Quarterly Gross Profit rose 62.55% year-over-year to $125.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.7 million (down 129.59% YoY) and the FY2025 annual result came in at -$1.0 million, down 100.46% from the prior year.
• Gross Profit was $125.2 million for Q1 2026 at Travere Therapeutics, up from -$354.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $125.2 million in Q1 2026 and bottomed at -$354.3 million in Q4 2025.
• A 5-year average of $27.2 million and a median of $38.4 million in 2025 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit jumped 118.11% — and 2025, when it slumped 590.48%.
• Travere Therapeutics' Gross Profit stood at $28.5 million in 2022, then surged by 42.23% to $40.5 million in 2023, then soared by 78.38% to $72.2 million in 2024, then slumped by 590.48% to -$354.3 million in 2025, then jumped by 135.35% to $125.2 million in 2026.
• Business Quant data shows TVTX's Gross Profit at $125.2 million in Q1 2026, -$354.3 million in Q4 2025, and $38.4 million in Q3 2025.